Drug Profile
Research programme: influenza A virus H1N1 vaccine - Takeda
Alternative Names: Vaccines against new forms of influenza - TakedaLatest Information Update: 23 Jul 2014
Price :
$50
*
At a glance
- Originator Inviragen
- Developer Takeda Pharmaceuticals USA
- Class Influenza A virus H1N1 vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Influenza A virus H1N1 subtype